Printer Friendly

AMYLIN PHARMACEUTICALS INC. SELLS 4.0 MILLION SHARES OF COMMON STOCK IN INITIAL PUBLIC OFFERING

 AMYLIN PHARMACEUTICALS INC. SELLS 4.0 MILLION SHARES
 OF COMMON STOCK IN INITIAL PUBLIC OFFERING
 SAN DIEGO, Jan. 17 /PRNewswire/ -- Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) announced that it has sold 4.0 million shares of common stock priced at $14 per share. Of the stock sold, 3,200,000 shares are being initially offered in the United States and Canada, and 800,000 shares are being offered initially outside of the United States and Canada. The underwriters for this offering are Morgan Stanley & Co. Inc. and Alex. Brown & Sons Inc. After the offering, Amylin will have approximately 16.8 million shares outstanding.
 Amylin Pharmaceuticals Inc. was founded in 1987 to develop novel therapeutics based upon amylin, a newly discovered hormone, which is believed to play a central role in the regulation of glucose metabolism. The company is developing products based on amylin physiology for the treatment of diabetes and associated health problems such as certain types of obesity.
 Copies of the prospectus can be obtained from the office of Morgan Stanley & Co. Inc., 1251 Avenue of the Americas, New York, NY 10020, or Alex. Brown & Sons Inc., 135 East Baltimore St., Baltimore, MD 21202.
 -0- 1/17/92
 /CONTACT: Linda Seaton or Richard Keatinge of The Gable Group, 619-234-1300, for Amylin Pharmaceuticals Inc./
 (AMLN) CO: Amylin Pharmaceuticals Inc. ST: California IN: MTC SU: OFR


DM-JL -- SD001 -- 0872 01/17/92 09:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 17, 1992
Words:233
Previous Article:MEDCROSS INVESTORS INCREASE PLEDGE TO $2 MILLION
Next Article:STONERIDGE RESOURCES, INC. ANNOUNCES DIRECTOR RESIGNATION
Topics:


Related Articles
AMYLIN PHARMACEUTICALS FILES PUBLIC OFFERING FOR 3.77 MILLION SHARES OF COMMON STOCK
AMYLIN PHARMACEUTICALS RAISES $30 MILLION IN COMMON STOCK OFFERINGS
Amylin Pharmaceuticals Plans to Sell $35 Million of Common Stock to the Public and Johnson & Johnson
Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $25 Million of Convertible Senior Notes.
Amylin Pharmaceuticals, Inc. Announces Pricing Of Convertible Senior Notes.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters